Joan Shen

Joan Huaqiong Shen is the founder and CEO of NeuShen Therapeutics, a clinical-stage biotech with R&D centers in Shanghai and Boston that develops treatments for psychiatric and neurological disorders. A physician-scientist trained in psychiatry and neurology, she spent decades leading central-nervous-system drug programs at Eli Lilly, Wyeth, Pfizer, Hengrui and Johnson & Johnson before running R&D and serving as CEO at I-Mab Biopharma, where she took the company public on Nasdaq and struck a global partnership with AbbVie. In 2026 NeuShen closed a Series A+ round led by Lilly Asia Ventures as its lead compound NS-136 advanced into Phase 2 trials.